Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer

References

• Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379: 432–44.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633–42.
   PubMed Web of Science ®Google Scholar
• Eckhoff L, Knoop AS, Jensen MB, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 2013;142:109–18.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011;125:767–74.
   PubMed Web of Science ®Google Scholar
• Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009;85: 155–63.
   PubMed Web of Science ®Google Scholar
• Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, et al. Abcb1 genetic variation influences the toxicity and clinical outcome of patients with androgen- independent prostate cancer treated with docetaxel. Clin Cancer Res 2008;14:4543–9.
   PubMed Web of Science ®Google Scholar
• Mir O, Alexandre J, Tran A, Durand JP, Pons G, Treluyer JM, et al. Relationship between gstp1 ile(105)val polymorphism and docetaxel-induced peripheral neuropathy: Clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009;20:736–40.
   PubMed Web of Science ®Google Scholar
• Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer. J Clin Oncol 2007;25:4528–35.
   PubMed Web of Science ®Google Scholar
• Booton R, Ward T, Heighway J, Ashcroft L, Morris J, Thatcher N. Glutathione-s-transferase p1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol 2006;1:679–83.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Spaggiari F, Indelli M, Lelli G, Baricordi OR, Rimessi P, et al. Association of cyp1b1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 2010;124:593–8.
   PubMed Web of Science ®Google Scholar
• Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194–203.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study. Gynecol Oncol 2009;113:264–9.
   PubMed Web of Science ®Google Scholar
• Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, et al. Effect of common cyp3a4 and cyp3a5 variants on the pharmacokinetics of the cytochrome p450 3a phenotyping probe midazolam in cancer patients. Clin Cancer Res 2005;11:7398–404.
   PubMed Web of Science ®Google Scholar
• Hayes JD, Strange RC. Glutathione s-transferase polymorphisms and their biological consequences. Pharmacology 2000;61:154–66.
   PubMed Web of Science ®Google Scholar
• Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 2010;10:191–9.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 2012;30: 3051–7.
   PubMed Web of Science ®Google Scholar
• Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978–89.
   PubMed Web of Science ®Google Scholar
• Peng Z, Wang Q, Gao J, Ji Z, Yuan J, Tian Y, et al. Association between gstp1 ile105val polymorphism and oxaliplatin- induced neuropathy: A systematic review and meta-analysis. Cancer Chemother Pharmacol 2013;72:305–14.
   PubMed Web of Science ®Google Scholar
• Vach W, Bergmann TK, Brosen K. No evidence for taxane/platinum pharmacogenetic markers: Just lack of power? J Clin Oncol 2008;26:1903–4; author reply 4–5.
   PubMed Web of Science ®Google Scholar
• Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51–88.
   PubMed Web of Science ®Google Scholar
• Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23:422–31.
   PubMed Web of Science ®Google Scholar
• Barriere DA, Rieusset J, Chanteranne D, Busserolles J, Chauvin MA, Chapuis L, et al. Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species production and trpa1 sensitization. Pain 2012;153: 553–61.
   PubMed Web of Science ®Google Scholar
• Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001;24:1050–7.
   PubMed Web of Science ®Google Scholar
• Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Res 2014;20:2466–75.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007;25:4707–13.
   PubMed Web of Science ®Google Scholar